PMID-sentid Pub_year Sent_text comp_official_name comp_offset protein_name organism prot_offset 6755123-9 1982 Dihydrotestosterone and/or thyroxine restores kallikrein to control levels. Dihydrotestosterone 0-19 kallikrein 1-related peptidase b9 Mus musculus 46-56 3649290-1 1987 The expression of many mouse kallikrein genes in the salivary gland is sexually dimorphic and inducible in females by administration of testosterone or thyroxine. Testosterone 136-148 kallikrein 1-related peptidase b9 Mus musculus 29-39 3649290-1 1987 The expression of many mouse kallikrein genes in the salivary gland is sexually dimorphic and inducible in females by administration of testosterone or thyroxine. Thyroxine 152-161 kallikrein 1-related peptidase b9 Mus musculus 29-39 2578523-2 1985 The glycosylation-enhancing factor (GEF) is a kallikrein-like enzyme and is purified by absorption to p-aminobenzamidine-Agarose followed by elution with benzamidine. 4-aminobenzamidine 102-120 kallikrein 1-related peptidase b9 Mus musculus 46-56 2578523-2 1985 The glycosylation-enhancing factor (GEF) is a kallikrein-like enzyme and is purified by absorption to p-aminobenzamidine-Agarose followed by elution with benzamidine. Sepharose 121-128 kallikrein 1-related peptidase b9 Mus musculus 46-56 2578523-2 1985 The glycosylation-enhancing factor (GEF) is a kallikrein-like enzyme and is purified by absorption to p-aminobenzamidine-Agarose followed by elution with benzamidine. benzamidine 109-120 kallikrein 1-related peptidase b9 Mus musculus 46-56 2578523-3 1985 Incubation of normal mouse mast cells with affinity-purified GEF or bradykinin, a product of cleavage of kininogen by kallikrein, resulted in the release of histamine and arachidonate from the cells. Histamine 157-166 kallikrein 1-related peptidase b9 Mus musculus 118-128 2578523-3 1985 Incubation of normal mouse mast cells with affinity-purified GEF or bradykinin, a product of cleavage of kininogen by kallikrein, resulted in the release of histamine and arachidonate from the cells. Arachidonic Acid 171-183 kallikrein 1-related peptidase b9 Mus musculus 118-128 6548955-2 1984 An oligonucleotide probe was used first to identify kallikrein-related sequences in a cDNA library derived from male mouse submaxillary gland mRNA. Oligonucleotides 3-18 kallikrein 1-related peptidase b9 Mus musculus 52-62 6548955-3 1984 Of 10,000 clones, 860 were identified as being kallikrein-related; these were analyzed further by hybridization to synthetic oligonucleotides using a procedure which eliminates the effects of base composition and thus allows distinction between partial and perfect sequence complementarity. Oligonucleotides 125-141 kallikrein 1-related peptidase b9 Mus musculus 47-57 6755123-9 1982 Dihydrotestosterone and/or thyroxine restores kallikrein to control levels. Thyroxine 27-36 kallikrein 1-related peptidase b9 Mus musculus 46-56 14219326-0 1964 [RESEARCH ON THE ACTION OF A KALLIKREIN AND TRYPSIN INHIBITOR ON THE COURSE OF EXPERIMENTAL HEPATITIS OF THE MOUSE DUE TO MHV-3]. mhv-3 122-127 kallikrein 1-related peptidase b9 Mus musculus 29-39 7317836-6 1981 One of the toxic components in the saliva was purified by isoelectric focusing and DEAE Sephadex A-50 chromatography and identified with a kallikrein-like enzyme. deae sephadex a 83-98 kallikrein 1-related peptidase b9 Mus musculus 139-149 32712319-4 2020 On the other hand, physiological activation of plasma prekallikrein in the kallikrein/kinin system on endothelial cells liberates bradykinin from associated high-molecular-weight kininogen to stimulate the constitutive bradykinin B2 receptor to generate nitric oxide and prostacyclin to induce vasodilation and counterbalance angiotensin II signaling from the renin-angiotensin system which stimulates vasoconstriction. Nitric Oxide 254-266 kallikrein 1-related peptidase b9 Mus musculus 57-67 32712319-4 2020 On the other hand, physiological activation of plasma prekallikrein in the kallikrein/kinin system on endothelial cells liberates bradykinin from associated high-molecular-weight kininogen to stimulate the constitutive bradykinin B2 receptor to generate nitric oxide and prostacyclin to induce vasodilation and counterbalance angiotensin II signaling from the renin-angiotensin system which stimulates vasoconstriction. Epoprostenol 271-283 kallikrein 1-related peptidase b9 Mus musculus 57-67 29467753-10 2018 In vitro analysis revealed that DSS-induced pKal activation, HK cleavage, and bradykinin plasma release were prevented by the absence of pKal or the inhibition of Kal. Dextran Sulfate 32-35 kallikrein 1-related peptidase b9 Mus musculus 45-48 23324381-4 2013 Studies in kallikrein-deficient mice indicate that kallikrein indeed influences blood pressure in the setting of mineralocorticoid excess and salt retention but not in normotensive animals and in high renin hypertension. Salts 142-146 kallikrein 1-related peptidase b9 Mus musculus 51-61 26469972-2 2015 Produced and released under its single chain form (sc), the sc-tPA can be cleaved by plasmin or kallikrein in a two chain form, tc-tPA. sc-tpa 60-66 kallikrein 1-related peptidase b9 Mus musculus 96-106 26469972-2 2015 Produced and released under its single chain form (sc), the sc-tPA can be cleaved by plasmin or kallikrein in a two chain form, tc-tPA. tc-tpa 128-134 kallikrein 1-related peptidase b9 Mus musculus 96-106 23280471-4 2013 RESULTS: Elevated expression of kallikrein was detected in the kidney and urine of tamoxifen-injected mice but not in controls. Tamoxifen 83-92 kallikrein 1-related peptidase b9 Mus musculus 32-42 23280471-7 2013 Tamoxifen-induced up-regulation of renal kallikrein expression increased nitric oxide production and dampened renal superoxide production and inflammatory cell infiltration, alluding to some of the pathways through which kallikreins may be operating within the kidneys. Tamoxifen 0-9 kallikrein 1-related peptidase b9 Mus musculus 41-51 23280471-7 2013 Tamoxifen-induced up-regulation of renal kallikrein expression increased nitric oxide production and dampened renal superoxide production and inflammatory cell infiltration, alluding to some of the pathways through which kallikreins may be operating within the kidneys. Nitric Oxide 73-85 kallikrein 1-related peptidase b9 Mus musculus 41-51 23280471-7 2013 Tamoxifen-induced up-regulation of renal kallikrein expression increased nitric oxide production and dampened renal superoxide production and inflammatory cell infiltration, alluding to some of the pathways through which kallikreins may be operating within the kidneys. Superoxides 116-126 kallikrein 1-related peptidase b9 Mus musculus 41-51 27551807-8 2016 Reducing the intracellular levels of glucosylceramide with a glucosylceramide synthase inhibitor resulted in decreased secretion of KALLIKREIN proteases by wild type keratinocytes, but not by smsk mutant keratinocytes. Glucosylceramides 37-53 kallikrein 1-related peptidase b9 Mus musculus 132-142 23324381-5 2013 These observations suggest that kallikrein can have antihypertensive function in physiological situations where sodium retention can trigger blood pressure elevation. Sodium 112-118 kallikrein 1-related peptidase b9 Mus musculus 32-42 22669897-1 2012 Tissue kallikrein (TK) is synthesized in arteries and distal renal tubule, the main target of aldosterone. Aldosterone 94-105 kallikrein 1-related peptidase b9 Mus musculus 7-17 23172304-3 2013 Mutations at the P1 (Arg(15)) site in combination with P2" (Met(17)) mutations profoundly affect inhibition of FXIa, plasmin, kallikrein, factor Xa and thrombin. Arginine 21-24 kallikrein 1-related peptidase b9 Mus musculus 126-136 22523247-3 2012 In the present study we hypothesized that the AT(2)R-stimulated increase in PRCP is mediated by the tyrosine phosphatase SHP-1, which in turn activates the PRCP-dependent prekallikrein-kallikrein pathway and releases bradykinin. Astatine 46-48 kallikrein 1-related peptidase b9 Mus musculus 174-184 22523247-3 2012 In the present study we hypothesized that the AT(2)R-stimulated increase in PRCP is mediated by the tyrosine phosphatase SHP-1, which in turn activates the PRCP-dependent prekallikrein-kallikrein pathway and releases bradykinin. galactose-1-phosphate 48-52 kallikrein 1-related peptidase b9 Mus musculus 174-184 22523247-5 2012 Activation of AT(2)R also enhanced conversion of plasma prekallikrein to kallikrein, and this effect was blunted by a small interfering RNA (siRNA) to SHP-1 and abolished by the tyrosine phosphatase inhibitor sodium orthovanadate. Sodium orthovanadate 209-229 kallikrein 1-related peptidase b9 Mus musculus 59-69 19508879-0 2009 Contact activation of kallikrein-kinin system by superparamagnetic iron oxide nanoparticles in vitro and in vivo. ferric oxide 67-77 kallikrein 1-related peptidase b9 Mus musculus 22-32 22367460-3 2012 Recent data indicate that kallikrein gene delivery reduces insulin resistance in STZ-treated rats suggesting a protective role for kinin in the development of diabetes. Streptozocin 93-96 kallikrein 1-related peptidase b9 Mus musculus 26-36 19508879-1 2009 Previously we reported that plasma kallikrein and high molecular weight kininogen attach to the surface of dextran-coated superparamagnetic iron oxide nanoparticles (SPION) through the incompletely covered iron oxide core (Simberg et al., Biomaterials, 2009). Dextrans 107-114 kallikrein 1-related peptidase b9 Mus musculus 35-45 19508879-1 2009 Previously we reported that plasma kallikrein and high molecular weight kininogen attach to the surface of dextran-coated superparamagnetic iron oxide nanoparticles (SPION) through the incompletely covered iron oxide core (Simberg et al., Biomaterials, 2009). ferric oxide 140-150 kallikrein 1-related peptidase b9 Mus musculus 35-45 19508879-1 2009 Previously we reported that plasma kallikrein and high molecular weight kininogen attach to the surface of dextran-coated superparamagnetic iron oxide nanoparticles (SPION) through the incompletely covered iron oxide core (Simberg et al., Biomaterials, 2009). ferric oxide 206-216 kallikrein 1-related peptidase b9 Mus musculus 35-45 9933620-4 1999 The ordered kallikrein loop projects proline toward the active site to restrict smaller residues or proline at the P2 position of substrates. Proline 37-44 kallikrein 1-related peptidase b9 Mus musculus 12-22 17636004-11 2007 Kallikrein and B2 receptor are major determinants of this cardioprotective effect of losartan. Losartan 85-93 kallikrein 1-related peptidase b9 Mus musculus 0-10 17137568-6 2007 Kallikrein treatment increased cardiac nitric oxide (NO) levels and reduced NAD(P)H oxidase activity and superoxide production. Nitric Oxide 39-51 kallikrein 1-related peptidase b9 Mus musculus 0-10 17137568-6 2007 Kallikrein treatment increased cardiac nitric oxide (NO) levels and reduced NAD(P)H oxidase activity and superoxide production. Superoxides 105-115 kallikrein 1-related peptidase b9 Mus musculus 0-10 11854276-6 2002 The loops include those stabilized by six disulfide bonds or a loop C (Gly(69)-Glu(80)) and an N-glycosylated kallikrein loop (His(91)-Ile(103)) not containing a site linked by a disulfide bond. Nitrogen 95-96 kallikrein 1-related peptidase b9 Mus musculus 110-120 11854276-8 2002 Second, disruptions of loop C and the N-linked oligosaccharide chain on the kallikrein loop affected the catalytic efficiency and P2 specificity, respectively. n-linked oligosaccharide 38-62 kallikrein 1-related peptidase b9 Mus musculus 76-86 9933620-3 1999 Neuropsin possesses an N-glycosylated "kallikrein loop" but forms six disulfide bonds corresponding to those of trypsin. Nitrogen 0-1 kallikrein 1-related peptidase b9 Mus musculus 39-49 19516248-2 2009 Here, we determined the role of the kallikrein-kinin system in the pathogenesis of streptozotocin-induced diabetic nephropathy in wild-type and tissue kallikrein-knockout mice. Streptozocin 83-97 kallikrein 1-related peptidase b9 Mus musculus 36-46 15796165-4 2005 FOY-305 (Foypan), a remedy for tumor pancreatitis, is a broad spectrum synthetic serine protease inhibitor which inhibits enzymatic activities including trypsin, thrombin, kallikrein and plasmin. camostat 0-7 kallikrein 1-related peptidase b9 Mus musculus 172-182 15796165-4 2005 FOY-305 (Foypan), a remedy for tumor pancreatitis, is a broad spectrum synthetic serine protease inhibitor which inhibits enzymatic activities including trypsin, thrombin, kallikrein and plasmin. camostat 9-15 kallikrein 1-related peptidase b9 Mus musculus 172-182 10845858-9 2000 Kallikrein gene transfer resulted in increases in urinary kinin, cGMP, and cAMP levels. Cyclic GMP 65-69 kallikrein 1-related peptidase b9 Mus musculus 0-10 10845858-9 2000 Kallikrein gene transfer resulted in increases in urinary kinin, cGMP, and cAMP levels. Cyclic AMP 75-79 kallikrein 1-related peptidase b9 Mus musculus 0-10 9933620-4 1999 The ordered kallikrein loop projects proline toward the active site to restrict smaller residues or proline at the P2 position of substrates. Proline 100-107 kallikrein 1-related peptidase b9 Mus musculus 12-22 7583049-0 1995 Furosemide treatment alters the distribution of kallikrein gene expression in kidneys of mice. Furosemide 0-10 kallikrein 1-related peptidase b9 Mus musculus 48-58 7583049-4 1995 Although the overall level of kallikrein gene expression was significantly greater in kidneys from furosemide-treated mice than in any other group, there was no detectable change in renal kallikrein gene expression in the submandibular glands after any of the treatments. Furosemide 99-109 kallikrein 1-related peptidase b9 Mus musculus 30-40 2076204-9 1990 The kallikrein activity responded differently to pH, to metal ions (zinc and copper), and to the sodium/potassium ratio, depending on the concomitant presence or absence of UT-like material. Metals 56-61 kallikrein 1-related peptidase b9 Mus musculus 4-14 2076204-9 1990 The kallikrein activity responded differently to pH, to metal ions (zinc and copper), and to the sodium/potassium ratio, depending on the concomitant presence or absence of UT-like material. Copper 77-83 kallikrein 1-related peptidase b9 Mus musculus 4-14 2076204-9 1990 The kallikrein activity responded differently to pH, to metal ions (zinc and copper), and to the sodium/potassium ratio, depending on the concomitant presence or absence of UT-like material. Sodium 97-103 kallikrein 1-related peptidase b9 Mus musculus 4-14 2076204-9 1990 The kallikrein activity responded differently to pH, to metal ions (zinc and copper), and to the sodium/potassium ratio, depending on the concomitant presence or absence of UT-like material. Potassium 104-113 kallikrein 1-related peptidase b9 Mus musculus 4-14 2495791-0 1989 Kallikrein stimulates arachidonic acid release and production of prostaglandins from TEA3A1 endocrine thymic epithelial cells. Arachidonic Acid 22-38 kallikrein 1-related peptidase b9 Mus musculus 0-10 2495791-0 1989 Kallikrein stimulates arachidonic acid release and production of prostaglandins from TEA3A1 endocrine thymic epithelial cells. Prostaglandins 65-79 kallikrein 1-related peptidase b9 Mus musculus 0-10 2495791-1 1989 Using TEA3A1 rat endocrine thymic epithelial cells, we demonstrated that kallikrein (EC 3.4.21.35) not only stimulated the release of arachidonic acid (AA) and its metabolites from TEA3A1 cells but also enhanced the intracellular synthesis of prostaglandin E2 (PGE2) and thromboxane B2 (TXB2) by approx. Arachidonic Acid 134-150 kallikrein 1-related peptidase b9 Mus musculus 73-83 2495791-1 1989 Using TEA3A1 rat endocrine thymic epithelial cells, we demonstrated that kallikrein (EC 3.4.21.35) not only stimulated the release of arachidonic acid (AA) and its metabolites from TEA3A1 cells but also enhanced the intracellular synthesis of prostaglandin E2 (PGE2) and thromboxane B2 (TXB2) by approx. Dinoprostone 243-259 kallikrein 1-related peptidase b9 Mus musculus 73-83 2495791-1 1989 Using TEA3A1 rat endocrine thymic epithelial cells, we demonstrated that kallikrein (EC 3.4.21.35) not only stimulated the release of arachidonic acid (AA) and its metabolites from TEA3A1 cells but also enhanced the intracellular synthesis of prostaglandin E2 (PGE2) and thromboxane B2 (TXB2) by approx. Dinoprostone 261-265 kallikrein 1-related peptidase b9 Mus musculus 73-83 2495791-1 1989 Using TEA3A1 rat endocrine thymic epithelial cells, we demonstrated that kallikrein (EC 3.4.21.35) not only stimulated the release of arachidonic acid (AA) and its metabolites from TEA3A1 cells but also enhanced the intracellular synthesis of prostaglandin E2 (PGE2) and thromboxane B2 (TXB2) by approx. Thromboxane B2 271-285 kallikrein 1-related peptidase b9 Mus musculus 73-83 2495791-1 1989 Using TEA3A1 rat endocrine thymic epithelial cells, we demonstrated that kallikrein (EC 3.4.21.35) not only stimulated the release of arachidonic acid (AA) and its metabolites from TEA3A1 cells but also enhanced the intracellular synthesis of prostaglandin E2 (PGE2) and thromboxane B2 (TXB2) by approx. Thromboxane B2 287-291 kallikrein 1-related peptidase b9 Mus musculus 73-83 2495791-8 1989 Furthermore, the effect of kallikrein was also totally abolished by adding pepstatin A, a known inhibitor of renin, pepsin and cathepsin D which does not inhibit kallikrein itself. pepstatin 75-86 kallikrein 1-related peptidase b9 Mus musculus 27-37 7749377-5 1994 Furthermore, in order to define whether brain kallikrein levels vary in the aging process, the hydrolyzing activity in the cerebrum L-prolyl-L-phenylalanyl-L-arginine-4-methyl-coumaryl-7-amide (Pro-Phe-Arg-MCA) was measured in young (7-week old) and old (36-week old) female senescence accelerated mice (SAM-P/8 and SAM-R/1). l-prolyl-l-phenylalanyl-l-arginine-4-methyl-coumaryl-7-amide 132-192 kallikrein 1-related peptidase b9 Mus musculus 46-56